Patient Reviews

Patient Reviews

Patient Reviews

[Anonymous] from China

Disease: Right lower lobe lung adenocarcinoma

Description of Condition:
In June 2022, I had unexplained right rib pain—simple treatment brought slight relief, but in November, I developed a cold-induced cough with sputum and intermittent chest/back pain that didn’t respond to anti-infection therapy. A January 2023 hospital exam delivered devastating news: a 38mm×30mm mass in my right lower lung, with metastases to my brain, bones, bilateral lungs and pleura, plus a sky-high CEA of 157ng/ml—I was diagnosed with advanced lung adenocarcinoma. I had one cycle of “pemetrexed + carboplatin” chemotherapy, but it did little— I stayed weak and kept coughing. Luckily, genetic testing found an EGFR exon19 mutation, so I started daily 80mg Osimertinib in February 2023. The drug worked gradually: pain eased and cough subsided. By May 2024, rechecks showed the primary tumor shrank, metastatic nodules/pleural effusion were nearly gone, brain metastases reduced, and CEA normalized. By June 2025, my condition remained stable—I could handle daily life independently with no serious side effects. I’m so grateful for choosing the right treatment.
Treatment Process:
In July 2018, I started first-line Osimertinib 80mg/day, but developed ILD symptoms on day 60—Osimertinib was discontinued immediately, and I took oral prednisone 60mg/day, with ILD symptoms relieved and lung lesions improved after 13 days. In February 2019, Osimertinib 80mg/day was restarted combined with prednisone 30mg/day (later gradually reduced to 3.75mg/day), followed by continuous monitoring of ILD recurrence and tumor progression through regular chest CT rechecks.
Recovery Situation:
After restarting Osimertinib, I took it continuously for over 16 months—my tumor didn’t progress and stayed in partial response (PR). What’s more, there was no recurrence of ILD; I only needed low-dose prednisone for maintenance, with no other serious adverse reactions and good tolerance.